- Home
- CNX vs ABVX Comparison
CNX vs ABVX Comparison
Compare CNX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- ABVX
- Stock Information
- Founded
- CNX 1860
- ABVX 2013
- Country
- CNX United States
- ABVX France
- Employees
- CNX N/A
- ABVX N/A
- Industry
- CNX Oil & Gas Production
- ABVX
- Sector
- CNX Energy
- ABVX
- Exchange
- CNX Nasdaq
- ABVX Nasdaq
- Market Cap
- CNX 4.6B
- ABVX 5.3B
- IPO Year
- CNX 1999
- ABVX N/A
- Fundamental
- Price
- CNX $29.38
- ABVX $88.38
- Analyst Decision
- CNX Hold
- ABVX Buy
- Analyst Count
- CNX 13
- ABVX 7
- Target Price
- CNX $32.08
- ABVX $74.86
- AVG Volume (30 Days)
- CNX 1.4M
- ABVX 999.1K
- Earning Date
- CNX 10-23-2025
- ABVX 08-11-2025
- Dividend Yield
- CNX N/A
- ABVX N/A
- EPS Growth
- CNX N/A
- ABVX N/A
- EPS
- CNX 0.97
- ABVX N/A
- Revenue
- CNX $1,813,319,000.00
- ABVX $11,444,012.00
- Revenue This Year
- CNX $42.66
- ABVX $25.23
- Revenue Next Year
- CNX $10.89
- ABVX N/A
- P/E Ratio
- CNX $30.17
- ABVX N/A
- Revenue Growth
- CNX 35.63
- ABVX 128.98
- 52 Week Low
- CNX $26.50
- ABVX $4.77
- 52 Week High
- CNX $41.93
- ABVX $86.07
- Technical
- Relative Strength Index (RSI)
- CNX 46.78
- ABVX 87.71
- Support Level
- CNX $28.70
- ABVX $78.00
- Resistance Level
- CNX $29.97
- ABVX $78.49
- Average True Range (ATR)
- CNX 0.58
- ABVX 3.31
- MACD
- CNX 0.22
- ABVX -0.43
- Stochastic Oscillator
- CNX 72.89
- ABVX 88.70
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.